Hyperion Biosystems, formerly known as C2Sense, develops advanced diagnostic and pharmaceutical security technologies. The company combines optical, molecular, and algorithmic innovation to improve detection, monitoring, and supply chain integrity.
Hyperion Biosystems is a Propel(x) alumni company. It first joined the platform in 2015. We’re proud to have supported the team early and to see how far the company has progressed.
Recent Milestones at Hyperion Biosystems Over the past year, Hyperion Biosystems has achieved several important milestones:
- Advanced the Halo reader platform and introduced Helios, a molecular platform for ctDNA and cfDNA detection
- Secured a second NIH RADx award, recognizing its continued innovation in diagnostics
- Entered a licensing agreement with Colorcon to commercialize on-dose authentication technology for pharmaceutical and nutraceutical markets
- Presented its technology to global health and security stakeholders, expanding real-world applications
Hyperion Biosystems continues to expand the impact of its diagnostic and authentication platforms across healthcare, pharmaceuticals, and supply chains.
At Propel(x), we’re excited to follow the next phase of Hyperion Biosystems’ growth.
Register on Propel(x) to learn more:
https://www.propelx.com/
